This relation of AGAT expression and clinical outcome in brain tumour patients, a tumour site in which methylating/alkylating agents have some utility, may not be applicable in other malignancies, where the mechanisms of chemotherapy resistance may be independent of AGAT expression (Middleton et al, 1998). The gene discussed is GATM; the disease is brain neoplasm.